Welcome to our dedicated page for NIKA PHARMACEUTICALS news (Ticker: NKPH), a resource for investors and traders seeking the latest updates and insights on NIKA PHARMACEUTICALS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NIKA PHARMACEUTICALS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NIKA PHARMACEUTICALS's position in the market.
Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) has acquired a production building and land valued at $2,045,209 in Sofia Province, Bulgaria. The company now owns Nika Europe, , which includes the production building and land. The building has a 18,669 square feet area with manufacturing halls, an office section, and various facilities. NIKA plans to construct laboratories and a manufacturing facility for injection drugs, complying with strict GMP standards. The company signed a Supply Agreement for a vial production line with a maximum capacity of 18,000 vials/h, expected to be operational by January 2025. CEO Dimitar Savov emphasizes the importance of having its own production to meet demand and generate profits for shareholders.
Summary not available.
Summary not available.